Poor compliance with germline testing recommendations in colorectal cancer patients undergoing molecular residual disease testing

Chromosome segregation of human nonhomologous Robertsonian translocations: insights from preimplantation genetic testing

Accuracy of fetal fraction measurements in a single nucleotide polymorphismbased noninvasive prenatal test

Role of genetic analysis of products of conception and PGT in managing early pregnancy loss

The Role of cfDNA Biomarkers and Patient Data in the Early Prediction of Preeclampsia: Artificial Intelligence Model

Reproductive Carrier Screening: Identifying Families at Risk for Familial Hypercholesterolemia in the United States

Clinical Validation of a Prenatal Cell-Free DNA Screening Test for Fetal RHD in a Large U.S. Cohort

Gilstrop Thompson, et al. OBSTETRICS & GYNECOLOGY 2024

Utilization of Circulating Tumor DNA in the Surveillance Setting

Gibbs JN, Dale PS, Weatherall AL. The American Surgeon. 2023

Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors

Kalashnikova E, Aushev, VA, Malashevich AK, et al. Molecular Oncology. 2023

Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer

Tsimberidou AM, Alayli FA, Okrah K, et al. Journal of Experimental Medicine. 2024

Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors

Hernando-Calvo A, Yang SYC, Vila-Casadesús M, et al. JCO Precis Oncol. 2024

Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma

Narkhede M, Tomassetti S, Iqbal M. Front. in Oncol 2024

Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma

Phillipps J, Nassief G, Morecroft R, et al. NPJ Precision Oncology. 2024

Early real-world experience monitoring circulating tumor DNA in resected early-stage non–small cell lung cancer

Martin T, Dinerman A, Sudhaman S, et al. J Thorac Cardiovasc Surg. 2024

Clinical significance of perioperative minimal residual disease detected by circulating tumor DNA in lung cancer patients with a long follow

Ohara S, Suda K, Sudhaman S, et al. JTO Cinical and Research Reports. 2024

ctDNA as an Adjunct to Posttreatment PET for Head and Neck Cancer Recurrence Risk Assessment

Lele SJ, Adilbay D, Lewis E, et al. Otolaryngology–Head and Neck Surgery. 2024

Post-surgical ctDNA-based molecular residual disease detection in patients with stage I uterine malignancies

F. Recio, C.S. Scalise, P. Loar et al. Gynecologic Oncology. 2024

Neoadjuvant atezolizumab plus chemotherapy in gastric and gastroesophageal junction adenocarcinoma: the phase 2 PANDA trial

Verschoor YL, van de Haar J, van den Berg JG, et al. Nat Med. 2024

A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC)

Dayyani F, Smith BR, Nguyen NT, et al. Future Oncol. 2022